ストックスクリーナーアプリを入手
83.86
0.01%
0.01
アフターアワーズ：
83.86
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
CRNX Downgraded by UBS -- Price Target Raised to $85.00 - GuruFocus
UBS downgrades Crinetics stock rating on Vertex acquisition By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Inc - TradingKey
CRNX|Crinetics Pharmaceuticals Inc|Price:83.865|Chg%:+0.135 - TradingKey
Crinetics Pharmaceuticals Inc (CRNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Crinetics Pharmaceuticals Inc (CRNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crinetics Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRNX - TradingView
Crinetics Pharmaceuticals Inc (CRNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Crinetics Pharmaceuticals Inc (CRNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRNX, SLP, NCSM, and PASG - Morningstar
Vertex was sole bidder in high-premium Crinetics acquisition - BioPharma Dive
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity - TipRanks
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunit - Benzinga
How Crinetics Pharmaceuticals Inc. (CRNX) Affects Rotational Strategy Timing - Stock Traders Daily
Vertex was only bidder for Crinetics in year’s second-highest M&A premium - Endpoints News
Vertex-Crinetics Pharmaceuticals deal faces Australian review - MLex
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NY - Supply Chain Digital
Crinetics Pharmaceuticals stock trades up to $83.90 as Everyday Advocacy resource launches, Crinetics - Traders Union
Crinetics Pharmaceuticals (CRNX) Piper Sandler 36th Annual Healthcare Conference summary - Quartr
CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030 - TradingView
Vertex, Crinetics Pharmaceuticals filed US premerger notifications July 20 - MLex
Crinetics Pharmaceuticals (NASDAQ: CRNX) backs $85-per-share cash sale to Vertex - Stock Titan
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Shareholder Alert: Ademi LLP investigates whether Crinetics - GlobeNewswire
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why - Sahm
Crinetics Pharmaceuticals (CRNX) Q2 2025 earnings summary - Quartr
Crinetics Pharmaceuticals (CRNX) R&D Day 2025 Summary - Quartr
Crinetics Pharmaceuticals (CRNX) Proxy filing Summary - Quartr
Monteverde investigates Element Solutions, Crinetics, and AstroNova sales - scanx.trade
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESI, CRNX, SOLS, and PATK - Sahm
Crinetics Pharmaceuticals (CRNX) Stock Looks Fully Valued While Returns Stay Very Strong - Sahm
Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal - Sahm
Halper Sadeh LLC is Investigating Whether ESI, CRNX, SOLS are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal - Yahoo Finance
After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - Benzinga
Crinetics Pharmaceuticals stock hits all-time high at 83.77 USD By Investing.com - Investing.com India
Crinetics Pharmaceuticals stock hits all-time high at 83.77 USD - Investing.com
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion - BioBuzz
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals - Yahoo Finance
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? - webull.com
Truist raises Vertex stock price target to $560 on Crinetics deal - Investing.com UK
Truist raises Vertex stock price target to $560 on Crinetics deal By Investing.com - Investing.com India
Drugmaker Vertex spends $10B to buy biotech firm to expand rare-disease offerings - Post and Courier
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crin - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crinetics Pharmaceuticals - GuruFocus
Vertex to buy Crinetics for $10 billion to expand rare-disease business - MSN
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse - TradingView
Crinetics Pharmaceuticals Announces Merger Agreement and Non-Compete Agreements With Key Executives - Minichart
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Crinetics Pharmaceuticals Announces Merger Agreement With Vertex - TipRanks
Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal - Stock Titan
Why This Pharmaceutical Stock Jumped Close to 100% This Week - The Motley Fool
Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’ - Sahm
Price to book forward of Crinetics Pharmaceuticals Inc – DUS:6Z4 - TradingView
Crinetics Pharmaceuticals (CRNX) to be Acquired by Vertex Pharma - GuruFocus
Why Crinetics Stock Soared 99% This Week - AOL.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) - PR Newswire
CNBC ‘Final Trades’: Nvidia, Vertex Pharmaceuticals And More OnRoundhill Memory ETF (BATS:DRAM) - Benzinga
1.49%
2.53%
大文字化:
|
ボリューム (24 時間):